In patients with DLB, a higher amyloid burden is associated with the diagnosis of dementia at a younger age, greater cognitive decline (Sarro et al., 2016), lower cognitive performance (Ferreira et al., 2020), decreased dopamine transporter (DAT) activity (Yoo et al., 2020), and more extensive gray matter atrophy (Sarro et al., 2016; Lee et al., 2018b). The gene discussed is SLC6A3; the disease is dementia.